Colon tumor removal showdown: which technique stops regrowth?
NCT ID NCT06815406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two procedures—EMR and ESD—for removing large, flat colon growths (called LST-G) that can turn into cancer. About 282 adults will be randomly assigned to one of the two methods. The goal is to see which technique leads to fewer growths coming back within a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 282 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2021
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of Laterally Spreading Tumor - Granular Type (LST-G) ≥ 20 mm in the colon or rectum with an indication for endoscopic resection. * Life expectancy \> 10 years. * Ability to understand and sign the informed consent form, demonstrating comprehension of the study and willingness to participate. Exclusion Criteria: * Diagnosis of Laterally Spreading Tumor - Non-Granular Type (LST-NG). * Presence of depressed areas within the lesion. * Lesions located on a scar or anastomosis site. * Lesions classified as Kudo Vi or Vn pattern. * History of chronic inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). * Diagnosis of hereditary polyposis syndromes (e.g., familial adenomatous polyposis, Lynch syndrome).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Azienda USL IRCCS di Reggio Emilia
RECRUITINGReggio Emilia, Italy
-
Ente Ospedaliero Ospedali Galliera
RECRUITINGGenova, Italy
-
IRCCS Azienda Ospedaliero Universitaria di Bologna - Sant'Orsola Malpighi
RECRUITINGBologna, Italy
-
Ospedale Civile di Baggiovara
RECRUITINGModena, Italy
-
Università Vita Salute - IRCCS
RECRUITINGMilan, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ivosidenib plus mFOLFOXIRI and celecoxib as a treatment for BRAF-targeted therapy-refractory BRAF V600E-mutant colorectal cancer patients: a phase II study
- Can a new drug shrink advanced solid tumors?
- Can a new drug shrink tumors that resist standard care?
- A single blood draw to detect five cancers before symptoms appear?
- Can a new drug duo shrink Hard-to-Treat tumors?
- Could a simple mineral calm the Body's Post-Surgery fire?